omcl-20211213

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 13, 2021

OMNICELL, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-33043

94-3166458

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer Identification Number)

590 East Middlefield Road

Mountain View, CA 94043

(Address of principal executive offices, including zip code)

(650) 251-6100

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.001 par value

OMCL

NASDAQ Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company									☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On December 13, 2021, Omnicell, Inc. (the “Company”) provided a written notice to the trustee and the noteholders of its 0.25% convertible senior notes due 2025 (the “Notes”) that it has irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000 (the “Combination Settlement”). As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000.

The Company has delivered the aforementioned notice in connection with the anticipated adoption of Accounting Standards Update 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) on January 1, 2022. Under ASU 2020-06, the accounting for convertible debt instruments such as the Notes is simplified by allowing for such convertible debt instruments to be accounted for as a single liability instrument measured at its amortized cost. In addition, under ASU 2020-06, the Company will no longer be allowed to use the treasury stock method for convertible instruments and instead will be required to apply the “if-converted” method for purposes of calculating diluted earnings per share. However, by irrevocably electing to fix its settlement method to the Combination Settlement as described above, only the shares issuable in respect of any conversion consideration in excess of the principal amount would be considered outstanding for purposes of the diluted earnings per share calculations under ASU 2020-06.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


			OMNICELL, INC.
Date: December 13, 2021			/s/ Peter J. Kuipers
			Peter J. Kuipers
			Executive Vice President and Chief Financial Officer

Omnicell, Inc. filed SEC Form 8-K: Other Events